174 related articles for article (PubMed ID: 29462869)
1. Modulation of VEGF-A Alternative Splicing as a Novel Treatment in Chronic Kidney Disease.
Stevens M; Oltean S
Genes (Basel); 2018 Feb; 9(2):. PubMed ID: 29462869
[TBL] [Abstract][Full Text] [Related]
2. The VEGF-A exon 8 splicing-sensitive fluorescent reporter mouse is a novel tool to assess the effects of splicing regulatory compounds
Stevens M; Star E; Lee M; Innes E; Li L; Bowler E; Harper S; Bates DO; Oltean S
RNA Biol; 2019 Dec; 16(12):1672-1681. PubMed ID: 31432737
[TBL] [Abstract][Full Text] [Related]
3. The anti-angiogenic isoforms of VEGF in health and disease.
Qiu Y; Hoareau-Aveilla C; Oltean S; Harper SJ; Bates DO
Biochem Soc Trans; 2009 Dec; 37(Pt 6):1207-13. PubMed ID: 19909248
[TBL] [Abstract][Full Text] [Related]
4. A drug-repositioning screen using splicing-sensitive fluorescent reporters identifies novel modulators of VEGF-A splicing with anti-angiogenic properties.
Star E; Stevens M; Gooding C; Smith CWJ; Li L; Ayine ML; Harper SJ; Bates DO; Oltean S
Oncogenesis; 2021 May; 10(5):36. PubMed ID: 33941763
[TBL] [Abstract][Full Text] [Related]
5. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors.
Nowak DG; Woolard J; Amin EM; Konopatskaya O; Saleem MA; Churchill AJ; Ladomery MR; Harper SJ; Bates DO
J Cell Sci; 2008 Oct; 121(Pt 20):3487-95. PubMed ID: 18843117
[TBL] [Abstract][Full Text] [Related]
6. Modulation of Receptor Tyrosine Kinase Activity through Alternative Splicing of Ligands and Receptors in the VEGF-A/VEGFR Axis.
Stevens M; Oltean S
Cells; 2019 Mar; 8(4):. PubMed ID: 30925751
[TBL] [Abstract][Full Text] [Related]
7. Regulation of alternative VEGF-A mRNA splicing is a therapeutic target for analgesia.
Hulse RP; Beazley-Long N; Hua J; Kennedy H; Prager J; Bevan H; Qiu Y; Fernandes ES; Gammons MV; Ballmer-Hofer K; Gittenberger de Groot AC; Churchill AJ; Harper SJ; Brain SD; Bates DO; Donaldson LF
Neurobiol Dis; 2014 Nov; 71():245-59. PubMed ID: 25151644
[TBL] [Abstract][Full Text] [Related]
8. VEGF-A165b is an endogenous neuroprotective splice isoform of vascular endothelial growth factor A in vivo and in vitro.
Beazley-Long N; Hua J; Jehle T; Hulse RP; Dersch R; Lehrling C; Bevan H; Qiu Y; Lagrèze WA; Wynick D; Churchill AJ; Kehoe P; Harper SJ; Bates DO; Donaldson LF
Am J Pathol; 2013 Sep; 183(3):918-29. PubMed ID: 23838428
[TBL] [Abstract][Full Text] [Related]
9. Anti-angiogenic isoform of vascular endothelial growth factor-A in cardiovascular and renal disease.
Kikuchi R; Stevens M; Harada K; Oltean S; Murohara T
Adv Clin Chem; 2019; 88():1-33. PubMed ID: 30612603
[TBL] [Abstract][Full Text] [Related]
10. VEGF-A
Stevens M; Neal CR; Salmon AHJ; Bates DO; Harper SJ; Oltean S
J Physiol; 2017 Oct; 595(19):6281-6298. PubMed ID: 28574576
[TBL] [Abstract][Full Text] [Related]
11. Alternative splicing in angiogenesis: the vascular endothelial growth factor paradigm.
Ladomery MR; Harper SJ; Bates DO
Cancer Lett; 2007 May; 249(2):133-42. PubMed ID: 17027147
[TBL] [Abstract][Full Text] [Related]
12. The role of VEGF 165b in pathophysiology.
Peiris-Pagès M
Cell Adh Migr; 2012; 6(6):561-8. PubMed ID: 23076130
[TBL] [Abstract][Full Text] [Related]
13. Splicing factor polymorphisms, the control of VEGF isoforms and association with angiogenic eye disease.
Carter JG; Cherry J; Williams K; Turner S; Bates DO; Churchill AJ
Curr Eye Res; 2011 Apr; 36(4):328-35. PubMed ID: 21309690
[TBL] [Abstract][Full Text] [Related]
14. The alternatively spliced anti-angiogenic family of VEGF isoforms VEGFxxxb in human kidney development.
Bevan HS; van den Akker NM; Qiu Y; Polman JA; Foster RR; Yem J; Nishikawa A; Satchell SC; Harper SJ; Gittenberger-de Groot AC; Bates DO
Nephron Physiol; 2008; 110(4):p57-67. PubMed ID: 19039247
[TBL] [Abstract][Full Text] [Related]
15. The natural drug DIAVIT is protective in a type II mouse model of diabetic nephropathy.
Stevens M; Neal CR; Craciun EC; Dronca M; Harper SJ; Oltean S
PLoS One; 2019; 14(3):e0212910. PubMed ID: 30865689
[TBL] [Abstract][Full Text] [Related]
16. Molecular diversity of VEGF-A as a regulator of its biological activity.
Woolard J; Bevan HS; Harper SJ; Bates DO
Microcirculation; 2009 Oct; 16(7):572-92. PubMed ID: 19521900
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor (VEGF) in the pathogenesis of diabetic nephropathy of type 1 diabetes mellitus.
Mironidou-Tzouveleki M; Tsartsalis S; Tomos C
Curr Drug Targets; 2011 Jan; 12(1):107-14. PubMed ID: 20735351
[TBL] [Abstract][Full Text] [Related]
18. Circulating levels of anti-angiogenic VEGF-A isoform (VEGF-Axxxb) in colorectal cancer patients predicts tumour VEGF-A ratios.
Bunni J; Shelley-Fraser G; Stevenson K; Oltean S; Salmon A; Harper SJ; Carter JG; Bates DO
Am J Cancer Res; 2015; 5(6):2083-9. PubMed ID: 26269767
[TBL] [Abstract][Full Text] [Related]
19. Stability and Species Specificity of Renal VEGF-A Splicing Patterns in Kidney Disease.
Turner RJ; Eikmans M; Bajema IM; Bruijn JA; Baelde HJ
PLoS One; 2016; 11(9):e0162166. PubMed ID: 27598902
[TBL] [Abstract][Full Text] [Related]
20. New Insights into VEGF-A Alternative Splicing: Key Regulatory Switching in the Pathological Process.
Dehghanian F; Hojati Z; Kay M
Avicenna J Med Biotechnol; 2014 Oct; 6(4):192-9. PubMed ID: 25414781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
